Beyond tumor response: hope and decision regret during immunotherapy for hepatocellular carcinoma
Supportive Care in Cancer · 2026-10 · 34 (10)
DOI: 10.1007/s00520-026-11228-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 20.09.2026. Verfasst von Huei-Shiuan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, College of Nursing, Taipei Medical University, No.250, Wuxing St., Xinyi Dist., Taipei, 11031, Taiwan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Hope, Immunotherapy. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Immunotherapy-targeted combination therapy has transformed hepatocellular carcinoma (HCC) treatment, yet longitudinal patient-reported outcome (PRO) trajectories remain poorly characterized. We prospectively examined decision regret, hope, fatigue and quality of life during first-line treatment. METHODS: This convergent mixed-methods study enrolled 33 patients initiating first-line immunotherapy-targeted therapy at a Taiwan medical center (December 2022-October 2023). PROs were assessed across six cycles using validated instruments, and all participants were interviewed. Strands were integrated through joint display analysis. RESULTS: Twenty-one patients (63.6%) completed six cycles; 12 (36.4%) discontinued. Completers maintained stable PROs with low regret, whereas discontinuers declined faster in EQ-5D utility (interaction B = - 0.169 per cycle, p = .007) and showed a larger, non-significant rise in regret (+ 9.58, p = .051, d = 0.50; between-group p = .042). Hope declined in both groups (- 1.48, p = .003), correlating negatively with regret (r = - .383, p = .028). Interviews centered on treatment-related discomfort (24/33), sustained hope for disease control (31/33) and financial strain (25/33); where regret was voiced (3/33) it concerned earlier points in the illness course rather than the current treatment decision. Integration yielded four expanded meta-inferences and one discordance, between measured and voiced regret. CONCLUSION: Treatment completers maintain stable PROs, but more than one-third discontinued and experienced worse fatigue and greater regret, supporting pre-treatment counselling that is honest and informative rather than reassuring. Discontinuation marks a psychologically vulnerable transition, while universal hope decline warrants psychosocial monitoring for all patients. Given the sample size, predictors of regret are hypothesis-generating.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Nursing, College of Nursing, Taipei Medical University, No.250, Wuxing St., Xinyi Dist., Taipei, 11031, Taiwan.
- Department of Nursing, College of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
- Institute of Health Policy & Management, College of Public Health, National Taiwan University, Taipei, Taiwan.
ORCID-Profile: Tsai-Wei Huang
Zitieren
APA
Wang, H. S., Cheng, A. L., Chen, J. H., & Huang, T. W. (2026). Beyond tumor response: hope and decision regret during immunotherapy for hepatocellular carcinoma. Supportive Care in Cancer, 34(10). https://doi.org/10.1007/s00520-026-11228-2
Vancouver
Wang HS, Cheng AL, Chen JH, Huang TW. Beyond tumor response: hope and decision regret during immunotherapy for hepatocellular carcinoma. Supportive Care in Cancer. 2026;34(10). doi:10.1007/s00520-026-11228-2
BibTeX
@article{Wang2026,
author = {Wang, Huei-Shiuan and Cheng, Ann-Lii and Chen, Jin-Hua and Huang, Tsai-Wei},
title = {Beyond tumor response: hope and decision regret during immunotherapy for hepatocellular carcinoma},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {10},
doi = {10.1007/s00520-026-11228-2}
}
EUVIMED